Cyclin D1 differential activation and its prognostic impact in patients with advanced breast cancer treated with trastuzumab.

ABSTRACT:

Introduction

We sought to determine the level of activation of the critical components of the cyclin D1-mediated pathway and to evaluate their prognostic significance across the different molecular subtypes of advanced breast cancer.

Patients and methods

The study population comprised 219 female patients with advanced breast cancer who had been found to have human epidermal growth factor receptor 2 (HER2)-positive disease by local testing and were all treated with trastuzumab-based regimens. For all tumours, central testing for HER2 was performed, and cyclin D1 gene (CCND1) amplification, mRNA and protein expression were assessed by FISH, quantitative real-time-PCR and immunohistochemistry, respectively. Prognostic impact on clinical endpoints was evaluated with Cox r

SUBMITTER: Mountzios G 

PROVIDER: S-EPMC6555606 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature